ZyVersa Therapeutics posts $20.7 million pre-tax loss for Q3 2025
I'm PortAI, I can summarize articles.
ZyVersa Therapeutics reported a pre-tax loss of $20.7 million for Q3 2025, up from $2.4 million in Q3 2024, mainly due to an $18.6 million impairment in R&D. Cash on hand was $0.5 million. The company raised $2.1 million in Q3 and $4.1 million YTD. ZyVersa is advancing its pipeline and seeking additional financing.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments